Tamoxifen Export Market Intelligence: India's 220 Suppliers Shipping to 104 Countries — TransData Nexus 2026

Q: Who are the top tamoxifen exporters from India?

The top tamoxifen exporters from India are: 1. EUGIA PHARMA SPECIALITIES LIMITED — $6.7M (45.3% market share); 2. PRATAP ORGANICS PRIVATE LIMITED — $2.8M (19.1% market share); 3. GRANULES INDIA LIMITED — $1.9M (12.7% market share); 4. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED — $830.4K (5.6% market share); 5. KHANDELWAL LABORATORIES PRIVATE LIMITED — $742.7K (5.0% market share). Together they account for 87.8% of India's total tamoxifen export value.

Q: What is the total export value of tamoxifen from India?

The total export value of tamoxifen from India is $14.7M USD, recorded across 3,139 shipment transactions from 220 active exporters to 104 destination countries. The average shipment value is $4.7K.

Q: Which countries import tamoxifen from India?

India exports tamoxifen to 104 countries worldwide. The top importing countries are: UNITED STATES (42.5% share, $6.3M), GERMANY (24.0% share, $3.5M), UNITED KINGDOM (11.1% share, $1.6M), BELGIUM (7.9% share, $1.2M), THAILAND (6.9% share, $1.0M). These five markets account for 92.4% of total export value.

Q: What is the HS code for tamoxifen exports from India?

The primary HS code for tamoxifen exports from India is 30049048. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of tamoxifen exports from India?

The average unit price for tamoxifen exports from India is $3.83 USD per unit, with prices ranging from $0.01 to $2094.02 depending on formulation, packaging, and order volume. The total market is valued at $14.7M across 3,139 shipments.

Q: Which ports handle tamoxifen exports from India?

The primary ports for tamoxifen exports from India are SAHAR AIR CARGO ACC (INBOM4) (24.7% of shipments), DELHI AIR CARGO ACC (INDEL4) (20.3% of shipments), SAHAR AIR (17.2% of shipments), DELHI AIR (9.6% of shipments), Bombay Air (5.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of tamoxifen?

India is one of the world's leading exporters of tamoxifen due to its large base of 220 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports tamoxifen to 104 countries, demonstrating 53% global market coverage.

Q: What certifications do Indian tamoxifen exporters need?

Indian tamoxifen exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import tamoxifen from India?

There are 377 registered buyers importing tamoxifen from India, spread across 104 countries. The repeat buyer rate is 52.5%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top tamoxifen supplier from India?

EUGIA PHARMA SPECIALITIES LIMITED is the leading tamoxifen exporter from India with a market share of 45.3% and total export value of $6.7M across 182 shipments. The top 5 suppliers together control 87.8% of total export value.

Suresh Sormare

Tamoxifen

India Pharmaceutical Trade Intelligence

$14.7M220 Suppliers104 CountriesHS 30049048

ExportsIndia → UNITED STATES42.5%India → GERMANY24.0%

ImportsUNITED STATES → India$2.0M GREECE → India$8.4K

#1 Supplier: EUGIA PHARMA #1 Buyer: AUROBINDO PHARMA

Tamoxifen Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Tamoxifen to the World

Between 2022 and 2026, India exported $14.7M worth of tamoxifen across 3,139 verified shipments to 104 countries — covering 53% of world markets in the Advanced Oncology segment. The largest destination is UNITED STATES (42.5%). EUGIA PHARMA SPECIALITIES LIMITED leads with a 45.3% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Tamoxifen export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Tamoxifen export data snapshot — $14.7M · 220 exporters · 104 countriesTransData Nexus · Indian Customs Data

Top Tamoxifen Exporters from India

220 active exporters · Ranked by export value

View all 220 →

Top Tamoxifen Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	EUGIA PHARMA SPECIALITIES LIMITED	$6.7M	182	5	45.3%
2	PRATAP ORGANICS PRIVATE LIMITED

Top Countries Importing Tamoxifen from India

104 destination markets · Ranked by import value

All 104 countries →

Top Countries Importing Tamoxifen from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$6.3M	42.5%
2	GERMANY	$3.5M	24.0%
3	UNITED KINGDOM	$1.6M	11.1%
4	BELGIUM	$1.2M	7.9%
5	THAILAND	$1.0M	6.9%
6	SRI LANKA	$120.5K	0.8%
7	MALTA	$105.6K	0.7%
8	SOUTH AFRICA	$74.4K	0.5%
9	LITHUANIA	$71.9K	0.5%
10	VENEZUELA	$52.9K	0.4%

UNITED STATES is India's largest tamoxifen export destination, absorbing 42.5% of total exports worth $6.3M. The top 5 importing countries — UNITED STATES, GERMANY, UNITED KINGDOM, BELGIUM, THAILAND — together account for 92.4% of India's total tamoxifen export value. The remaining 99 destination countries collectively receive the other 7.6%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Tamoxifen to India?

7 origin countries · Total import value: $2.0M

India imports tamoxifen from 7 countries with a combined import value of $2.0M. The largest supplier is UNITED STATES ($2.0M, 13 shipments), followed by GREECE and SWITZERLAND. All values are from Indian Customs (DGFT) import records.

Countries Supplying Tamoxifen to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$2.0M	13	99.3%
2	GREECE	$8.4K	3	0.4%
3	SWITZERLAND	$4.2K	4	0.2%
4	ISRAEL	$2.1K	17	0.1%
5	UNITED KINGDOM	$335	1	0.0%
6	GERMANY	$7	1	0.0%
7	CYPRUS	$0	1	0.0%

UNITED STATES is the largest supplier of tamoxifen to India, accounting for 99.3% of total import value. The top 5 origin countries — UNITED STATES, GREECE, SWITZERLAND, ISRAEL, UNITED KINGDOM — together supply 100.0% of India's tamoxifen imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Tamoxifen

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

Tamoxifen has been a cornerstone in breast cancer treatment in the United States, with numerous Abbreviated New Drug Applications (ANDAs) approved by the FDA. For instance, Teva Pharmaceutical Industries Ltd. received final FDA approval for Tamoxifen Citrate 10 mg tablets on June 1, 2000. The regulatory pathway for Tamoxifen involves demonstrating bioequivalence to the reference listed drug, ensuring safety and efficacy. Given the substantial number of Indian exporters (220) supplying Tamoxifen to the U.S., compliance with FDA regulations, including Good Manufacturing Practices (GMP) and periodic inspections, is imperative to maintain market access.

2EU & UK Regulatory Framework

In the European Union, Tamoxifen is subject to stringent regulatory oversight. The European Medicines Agency (EMA) conducts periodic safety update report single assessments (PSUSAs) for Tamoxifen, with the most recent procedure (PSUSA/00002846/202504) resulting in a variation to the marketing authorization in March 2026. (ema.europa.eu) Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees Tamoxifen's market authorization. For example, in June 2025, Wockhardt UK Ltd. recalled a batch of Tamoxifen 20 mg film-coated tablets due to a dissolution failure identified during stability testing. (gov.uk) Compliance with EU GMP requirements is mandatory for manufacturers exporting to these markets, ensuring product quality and patient safety.

3WHO Essential Medicines & Global Standards

Tamoxifen is included in the 24th WHO Model List of Essential Medicines, published in September 2025, underscoring its critical role in global health. (who.int) This inclusion signifies its importance in treating priority health conditions worldwide. Manufacturers must adhere to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure product quality and facilitate global distribution.

4India Regulatory Classification

In India, Tamoxifen is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for Tamoxifen exports, ensuring compliance with national regulations and monitoring of pharmaceutical exports.

5Patent & Exclusivity Status

The primary patents for Tamoxifen have expired, leading to a competitive generic market. However, companies continue to develop novel formulations and derivatives. For instance, in April 2025, Atossa Therapeutics announced the issuance of U.S. Patent No. 12,281,056, covering various formulations of its (Z)-endoxifen portfolio, a potent Selective Estrogen Receptor Modulator (SERM). This indicates ongoing innovation in the field, potentially impacting the competitive landscape.

6Recent Industry Developments

In June 2025, the MHRA issued a Class 3 medicines recall for Tamoxifen 20 mg film-coated tablets produced by Wockhardt UK Ltd., following the identification of a dissolution failure during stability testing. (gov.uk) This underscores the importance of stringent quality control measures for manufacturers.

In March 2026, the EMA concluded a periodic safety update report single assessment (PSUSA/00002846/202504) for Tamoxifen, resulting in a variation to the marketing authorization. (ema.europa.eu) This highlights the continuous regulatory scrutiny to ensure the safety and efficacy of Tamoxifen in the European market.

These developments emphasize the dynamic regulatory environment surrounding Tamoxifen, necessitating vigilant compliance and quality assurance from manufacturers and exporters.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Tamoxifen

Retail & reference prices across 9 markets vs. India FOB export price of $3.83/unit

Global Price Benchmark for Tamoxifen across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$0.68	USD	According to the FDA's Orange Book, tamoxifen is an approved generic medication, contributing to its affordability in the U.S. market.
United Kingdom	$0.33	GBP	The NHS Drug Tariff lists tamoxifen as a standard treatment, ensuring its availability at regulated prices within the UK healthcare system.
Germany	$0.35	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) includes tamoxifen in its list of essential medicines, reflecting its established role in oncology treatment protocols.
Australia

Supply Chain Risk Assessment — Tamoxifen

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Tamoxifen, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, highlighting a significant dependency. This reliance poses a substantial risk, as any disruption in the supply chain from China can directly impact the availability and production of Tamoxifen in India.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, escalating conflicts in the Middle East led to the closure of the Strait of Hormuz, a critical maritime route for global trade. This disruption has caused significant delays and increased costs in shipping, affecting the timely import of APIs and KSMs into India. Consequently, the production schedules for Tamoxifen have been adversely affected, leading to potential shortages in both domestic and international markets.

2Supplier Concentration & Single-Source Risk

The export market for Tamoxifen from India is highly concentrated, with the top five exporters accounting for 87.8% of the total export value. EUGIA PHARMA SPECIALITIES LIMITED leads with a 45.3% share, followed by PRATAP ORGANICS PRIVATE LIMITED (19.1%), GRANULES INDIA LIMITED (12.7%), BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED (5.6%), and KHANDELWAL LABORATORIES PRIVATE LIMITED (5.0%). This high concentration indicates a significant single-source risk, as any operational or financial issues within these key companies could disrupt the global supply of Tamoxifen.

Access Complete Tamoxifen Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 3,139 transactions across 104 markets.

Request Demo View Pricing

Frequently Asked Questions — Tamoxifen Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top tamoxifen exporters from India?

The leading tamoxifen exporters from India are EUGIA PHARMA SPECIALITIES LIMITED, PRATAP ORGANICS PRIVATE LIMITED, GRANULES INDIA LIMITED, and 11 others. EUGIA PHARMA SPECIALITIES LIMITED leads with 45.3% market share ($6.7M). The top 5 suppliers together control 87.8% of total export value.

What is the total export value of tamoxifen from India?

The total export value of tamoxifen from India is $14.7M, recorded across 3,139 shipments from 220 active exporters to 104 countries. The average shipment value is $4.7K.

Which countries import tamoxifen from India?

India exports tamoxifen to 104 countries. The top importing countries are UNITED STATES (42.5%), GERMANY (24.0%), UNITED KINGDOM (11.1%), BELGIUM (7.9%), THAILAND (6.9%), which together account for 92.4% of total export value.

What is the HS code for tamoxifen exports from India?

The primary HS code for tamoxifen exports from India is 30049048. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Tamoxifen

Tamoxifen

Top Tamoxifen Exporters from India

Top Countries Importing Tamoxifen from India

Who Supplies Tamoxifen to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Tamoxifen

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Tamoxifen

Supply Chain Risk Assessment — Tamoxifen

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Tamoxifen Trade Intelligence

Frequently Asked Questions — Tamoxifen Exports from India

Who are the top tamoxifen exporters from India?

What is the total export value of tamoxifen from India?

Which countries import tamoxifen from India?

What is the HS code for tamoxifen exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of tamoxifen exports from India?

Which ports handle tamoxifen exports from India?

Why is India a leading exporter of tamoxifen?

What certifications do Indian tamoxifen exporters need?

How many buyers import tamoxifen from India?

What is the market share of the top tamoxifen exporter from India?

Analysis Methodology